KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the lung. There are presently no clinically proven strategies for treatment of KRAS--driven lung cancer. Activating mutations in KRAS are thought to confer independence from upstream signaling, however recent data suggest that this independence may not be absolute. Here we show that initiation and progression of KRAS--driven lung tumors requires input from ERBB family RTKs: Multiple ERBB RTKs are expressed and active from the earliest stages of KRAS driven lung tumor development, and treatment with a multi--ERBB inhibitor suppresses formation of KRas G12D --driven lung tumors. We present evidence that ERBB activity amplifies signaling through the core RAS pathway, supporting proliferation of KRAS mutant tumor cells in culture and progression to invasive disease in vivo. Importantly, brief pharmacological inhibition of the ERBB network significantly enhances the therapeutic benefit of MEK inhibition in an autochthonous tumor setting. Our data suggest that lung cancer patients with KRAS-driven disease may benefit from inclusion of multi--ERBB inhibitors in rationally designed treatment strategies.
Introduction
Cancers of the lung account for over 1.5 million deaths per annum worldwide and 5--year survival rates remain between 10 & 15% in many developed countries [1] . The majority of lung cancers are classified as non--small cell (NSCLC) and adenocarcinoma is the most common histological subtype of NSCLC. Activating mutations in KRAS occur in a third of lung adenocarcinoma (LuAd) cases [2] . RAS proteins have historically proven to be elusive targets for selective inhibition, although the recent development of G12 mutant KRAS--selective tool compounds suggests that therapeutic targeting of KRAS may in time be possible [3, 4] . In the interim, there is a pressing need to develop alternative strategies for more effective treatment of KRAS--driven disease.
The ERBB family of receptor tyrosine kinases comprises 4 members, EGFR (ERBB1), HER2 treatment of mice from 2 weeks post allele induction almost completely suppressed the emergence of tumors, indicating that the combination of endogenously expressed KRas G12D and constitutively expressed MYC requires input from ERBB RTKs in order to give rise to lung tumors ( Fig. 1G, H) . In contrast, daily Erlotinib treatment failed to show the same effect, consistent with reports that EGFR inhibition in isolation is ineffective in KRAS--driven lung cancer [15, 18] .
Progression of KRas--driven lung tumors is associated with increased ERBB network expression
The above analysis was performed on tumors at 5--6 weeks post Adeno--CRE--mediated allele activation. At this time post induction, the lungs of all induced KM mice contain dozens of individual tumors that present with uniform histology resembling human papillary adenocarcinoma in situ ( Fig. 2A, panel i) . A small minority of tumors (2--5%) also contain a second, more disorganized population with more aggressive histological features, including increased cytosolic and nuclear volume, prominent nucleoli, and increased morphological heterogeneity ( Fig. 2A , panel ii). IHC analysis revealed continuous expression of the same lineage markers across both populations in individual tumors, suggesting that the second populations represent the emergence of aggressive sub--clones ( Fig. S1B ). Progression of KRas G12D --driven lung tumors to more aggressive disease is associated with a pronounced increase in Erk1/2 phosphorylation [23, 24] . Accordingly, IHC analysis of phospho--Erk (p--Erk) levels revealed sharply higher expression of p--Erk in these disorganized sub--clones compared with the rest of the same tumors, and indeed across the entire tumor population ( Fig. 2A & B) .
By comparison, KM tumors harvested at 4--6 months post--induction showed widespread expression of p--Erk, as these more aggressive sub--clones gradually come to predominate ( Fig.  2B , panel iii). Moreover, KM metastases to the liver also show high levels of epithelial p--Erk staining (Fig. 2C ). Increased p--Erk levels were previously shown to be associated with amplification of the mutant KRas locus in a KP lung cancer model wherein KRas G12D expression was combined with loss of functional p53 [25] . We used laser--capture micro--dissection coupled with RNA--SEQ analysis to compare gene expression in p--Erk Low with p--Erk High KM tumor regions from 4
individual mice (see schematic, Fig.  S1C ). Expression of KRas was modestly higher (< 2 fold) in pErk High tumor regions, suggesting that locus amplification is not the underlying driver of progression in the KM model ( Fig. 3A ). Strikingly, we detected a sharp increase in expression of promiscuous ERBB--family ligands, Epiregulin (Ereg) and Amphiregulin (Areg), along with more modest but significant increases in HbEgf and Tgfa ( Fig. 3B --D and Fig. S1D ). Elevated expression of Ereg and Areg were previously reported to be associated with more aggressive tumors in a titrated model of KRas--driven mammary cancer [26] 
ERBB signaling amplifies RAS pathway activity in KRAS mutant human NSCLC cells
Combined inhibition of both EGFR and ERBB2 is required to prevent outgrowth of MEK inhibitor--resistant clones of human KRAS mutant NSCLC cells, however the effect of multi--ERBB inhibition on treatment--naïve cells was not previously explored [20] . Treatment of multiple KRAS mutant human NSCLC lines with the multi--ERBB inhibitor Neratinib suppressed proliferation in a dose--dependent manner (Fig.  4A ). In contrast, inhibition of EGFR in isolation showed little effect. Immunoblotting confirmed that the doses of Neratinib used strongly suppressed activity of ERBB RTKs (Fig. 4B ). Consistent with previous reports that Neratinib drives increased ERBB turnover [32], ERBB2 and ERBB3 protein expression were also reduced by Neratinib in multiple cell lines. Despite the presence of G12 mutant KRAS in all such cells, Neratinib consistently reduced levels of phosphor--ERK, suggesting that ERBB signaling amplifies RAS pathway activity even in cells expressing mutant KRAS ( Fig. 4B & S3A ). We therefore examined RAF binding as a direct measure of RAS signaling activity in A549 cells that are homozygous for mutant KRAS. Acute ERBB inhibition reduced RAS:RAF binding by some 50%, consistent with the observed partial reduction in p--ERK levels ( Fig. 4C ). Additionally, murine lung tumor cells carrying a spontaneously amplified KRas G12D allele also showed sensitivity to Neratinib, albeit somewhat lower than that of cells carrying a single copy of the allele (Fig. S3B ).
Together these results suggest that sensitivity to ERBB suppression is imparted through both mutant and wild--type KRAS.
To gain further mechanistic insight into the growth inhibitory effects of Neratinib, we Table  S1 ). Significantly, in all three cell lines, ERBB inhibition reduced expression of the same ERBB ligands that increased as KM tumors progress to p--Erk High disease. Taken together, ERBB activity thus establishes a feed--forward loop that sustains KRAS mutant NSCLC proliferation in vitro and drives tumor progression in vivo, at least in part by amplifying signaling through the core RAS--ERK module.
ERBB inhibition enhances the potency of MEK inhibition in vitro and extends survival of mice with LuAd
With the exception of H358 cells, ERBB inhibition did not alone result in death of KRAS mutant NSCLC cells in vitro, however, Neratinib significantly increased apoptosis induced by inhibition of MEK downstream of KRAS in multiple cell lines ( Fig. 5A ). Substitution of Neratinib with a second multi--ERBB inhibitor, Afatinib, perfectly replicated the effects of Neratinib, confirming the on--target specificity of the drug (Fig.  S3C,  D) . Moreover, both drugs combined with MEK inhibition to suppress colony formation ( Fig. 5B ). Consistent with published results [20] MEK inhibition alone increased expression of ERBB2 and ERBB3 in vitro, although the effect on ERBB2 phosphorylation was variable across the cell lines tested. Importantly, co--treatment with Neratinib continued to suppress both expression and activity of ERBB2 and ERBB3, while also suppressing EGFR activity (Fig. 5C ).
The combination of MEK and multi--ERBB inhibition was previously shown to suppress the growth of sub--cutaneous NSCLC xenografts under continuous daily treatment [20] , (Fig. S4 ). We conclude from these data that multi--ERBB inhibition may benefit LuAd patients with mutant KRAS--driven disease, if used in combination with other agents such as MEK inhibitors.
Discussion
EGFR--selective inhibitors have failed to show clinical benefit in mutant KRAS--driven cancers. In contrast with targeted inhibition of EGFR in isolation, we show here that broad inhibition of the ERBB network, using the multi--ERBB inhibitor Neratinib, almost completely suppresses formation of KRas G12D --driven lung tumors. We show that ERBB activity enhances signaling though the core RAS-->ERK pathway, establishing a feed--forward loop that is associated with progression to invasion and metastasis. Importantly, we show that brief, transient inhibition of ERBB signaling significantly enhances the therapeutic benefit of MEK inhibition in the autochthonous setting. Although this latter result is broadly supportive of the clinical implications of a prior study showing that increased ERBB activity underlies resistance to MEK inhibition [20] , our data are fundamentally distinct in that we demonstrate a clear role for ERBB activity from the very outset of KRAS--driven tumor initiation, as opposed to in reaction to targeted inhibition of MEK.
In the course of preparing this manuscript we became aware of an independent study that strongly complements our observations and underscores our conclusions: The work by Moll and colleagues similarly demonstrates a requirement for ERBB signaling to support progression of KRas G12D --driven lung cancer in vivo [34] . Importantly, their study utilized an independent pan--ERBB inhibitor, Afatinib, in the context of both KRas G12D --only and KRas G12D ;p53 Fl/Fl --driven tumor models. The striking similarities in the two studies attests to the on--target specificity of the 2 drugs used while also showing that the effects are independent of the genetic strategy used to accelerate KRas--driven disease and are therefore likely to have broader potential application.
Previous work has revealed that threshold levels of KRAS signaling are required for tumor initiation and progression. In a titratable model of HRas G12V overexpression in mammary glands, focal tumors arising spontaneously from non--transformed epithelium that expressed the transgene at low levels exhibited a pronounced increase in expression of both the HRas G12V transgene and of multiple ERBB ligands, including Ereg, Tgfa and HbEgf, again suggestive of feed--forward signal amplification [26] . More recently, this same "activity threshold" principle was shown to apply to MAPK (ERK) signaling as the key oncogenic effector pathway of KRAS in the lung [35] . Through pharmacological enhancement of MAPK activity, this study showed that different airway cell types require distinct levels of MAPK signaling for oncogenic transformation by mutant KRas, and that a second, higher, threshold signal was needed for progression to carcinoma. The existence of this higher threshold in KRas--driven LuAd was already clear from the pronounced increase in phosphor--Erk levels associated with tumor progression [26] which, in the KP model, is driven by spontaneous amplification of the G12D mutated allele [25] . Our data suggest that ratcheting up ERBB signal transduction provides an alterative route to RAS pathway signal amplification, independent of KRAS gene amplification. This is supported by our analysis of human data that shows a trend towards mutual exclusivity of ERBB ligand overexpression and amplification of mutant KRAS. It is important to note that, from the human data, there does not appear to be a preferred mechanism of ERBB signal enhancement -overexpression of ligands, amplification of RTKs and/or accessory molecules could all plausibly achieve the same effect. What is clear from these data is that the potential to increase ERBB signaling appears to be widespread in KRAS mutant human LuAd. Perhaps the most surprising observation is that endogenously expressed KRas G12D requires basal signaling from ERBB RTKs in order to initiate lung tumors, even when accompanied by MYC overexpression. Note that we previously showed that expression from the Rosa26 locus is refractory to growth factor signaling [36] - thus the requirement for ERBB activity does not reflect an artificial need for ERBB to sustain expression of the MYC transgene.
Instead, these data suggest that G12 mutant KRAS requires a push from upstream RTKs in order to breach the initial threshold needed for tumor initiation. Supporting this hypothesis, it was recently shown that G12 mutant KRAS, although no longer responsive to RAS--GAPs, does retain some level of intrinsic GTPase activity and thus cycles slowly between on and off states [4] , opening the possibility for upstream signaling to influence activity, either directly or by promoting activity of RAS guanonucleotide exchange factors (GEFs). Alternatively, tonic signal transduction through wild--type RAS isoforms may need to combine with that from mutant KRAS to likewise breach the threshold for transformation [37] . Our data presently do not distinguish between these possibilities and, indeed, they may not be mutually exclusive.
Activating mutations in KRAS are currently considered grounds for exclusion from clinical treatment with EGFR/ERBB inhibitors, while single--agent trials of the same drugs have failed to show efficacy outwith of cohorts with activating mutations in EGFR or ERBB amplification [38] . Indeed, our data concur that multi--ERBB inhibitors are unlikely to benefit KRAS--driven cancer patients if used in isolation. However, we show here the potential for such drugs to sensitize autochthonous KRAS--driven tumors to additional therapeutic agents, in this case to the MEK inhibitor Trametinib. Our data argue that clinical use of multi--ERBB inhibitors as part of an inhibitor cocktail to treat KRAS--driven LuAd deserves re--examination. Trametinib was administered in peanut oil at 1mg/kg. Live imaging of iRFP positive tumor-bearing mice was performed using a PEARL imaging system (Licor). All mice were sacrificed humanely using a schedule 1 procedure.
Materials and Methods

Immunohistochemistry and Tissue Analysis
Mouse tissues were perfusion fixed in zinc formalin overnight. 4µm paraffin sections were de-- 
